Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Theralase expands into china rw - 10 01 2012


Published on


  • Be the first to comment

  • Be the first to like this

Theralase expands into china rw - 10 01 2012

  1. 1. Press Release Theralase Expands Into ChinaToronto, Ontario, Canada – October 2, 2012, Theralase Technologies Inc. (TSXV: TLT) announced todaythat it has expanded the distribution of Theralase products into mainland China by signing an exclusivedistribution agreement with an active, established Chinese medical device distributor, Chengdu DisiIndustrial Co. Ltd. (Chengdu Disi).Under the terms of an exclusive distribution agreement, Chengdu Disi will market, sell and providecustomer support on Theralase therapeutic lasers to government, public and private hospitals, inChina, training them in the safe and effective operation of this cutting edge technologyTheralase will train Chengdu Disi’s sales, marketing and clinical personnel in the safe and effectiveoperation of Theralase therapeutic lasers, as well as be the exclusive supplier to Chengdu Disi, inexchange for Chengdu Disi achieving specific minimum sales performance.Prior to July 1, 2013, Chengdu Disi and Theralase will commit to binding minimum performance salescriteria for a further 3 years to allow Chengdu Disi the ability to maintain their exclusivity.Sales estimates for the first year commencing July 1, 2013 are planned to exceed $USD 1 million.Roger Dumoulin-White, President and CEO, stated “Chengdu Disi is a well established Chinese medicalproducts distribution company that will introduce the Theralase brand to a large group of government,public and private hospitals. China’s current population, the world’s largest at 1.34 billion, reports anannual growth rate of 9.2%, with current GDP in excess of $USD 11 trillion annually. It also boasts theworld’s fourth largest medical device market with annual sales in excess of $USD 14.8 billion.”Roger Dumoulin-White, President & CEO of Theralase went on to say, “China is just one of the majorworld markets, along with the U.S., that Theralase is currently pursuing to expand our internationaldistribution network. We are presently negotiating with a number of other worldwide medical devicedistributors who have expressed their interest in distributing the Theralase brand.”Mr. Shengcai Xiong, President of Chengdu Disi Industrial Co. Ltd. stated, “We were impressed withTheralase’s superpulsed laser system from the beginning and the dominance of the Theralase brandover other competitive products. Theralase’s scientific, clinical and technical knowledge on the subjectof therapeutic lasers was unparalleled in the industry and combined with Theralase’s ability to be theonly product on the market that can activate all three known cellular pathways promoting cellularregeneration up to 4 inches into tissue, we were convinced that Theralase was the right partner for us.We are pleased to partner with Theralase to rollout the Theralase brand in China and are confidentthat we will be successful in this endeavour. We have long-term relationships with numerousgovernment, public and private hospitals and will be able to proactively promote the Theralase brandto this market. Alternative medicine is embraced in the Chinese market having been the birthplace ofacupuncture and we strongly feel that Theralase’s leading edge technology will be well accepted andadopted at all levels of medicine in China.”
  2. 2. Press ReleaseAbout Chengdu Disi Industrial Co. Ltd.:Chengdu Disi Industrial Co. Ltd., founded in 1994, has developed a reputation for launching newproducts through its distribution network in China, having worked with Fortune 500 companies,distributing retail and commercial products throughout China. Chengdu Disi Industrial has a 2,000 sq.ft. sales, marketing and customer support facility in the business district of Chengdu, the capital ofSichuan province located in the heart of Southwest China. The company is well capitalized and has builtstrong contacts with the medical community.About Theralase Technologies Inc.:Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralasetechnology is safe and effective in treating pain, inflammation and for tissue regeneration of neuralmuscular skeletal conditions and wound healing in both humans and animals. Theralase complies withall FDA, Health Canada, CE and international regulatory approvals to ensure effective, safe and highquality products. Theralase also develops patented Photo Dynamic Compound (PDC) technologyfocused at targeting and destroying cancers, bacteria and viruses when light activated by Theralase’sproprietary and patented laser technologies.For further information please visit, regulatory filings may be viewed by press release contains forward-looking statements, which reflect the Companys current expectations regarding future events. The forward-lookingstatements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation toupdate these forward-looking statements.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) acceptsresponsibility for the adequacy or accuracy of this release.For More Information, please contact:Roger Dumoulin-White,President and CEO416-447-8455 ext. 225rwhite@theralase.comKristina HacheyChief Financial Officer416-447-8455 ext. 224khachey@theralase.comGreg BewshDirector of Investor Relations416-447-8455 ext. 262gbewsh@theralase.comArkady Mandel
  3. 3. Press ReleaseChief Scientific Officer416-447-8455 ext.